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CASE REPORTS

Resolution of Severe Obstructive Sleep Apnea after Treatment
of Anti-Muscle Kinase Receptor-Positive Myasthenia Gravis
Despite 60-Pound Weight Gain
Michael Morgenstern, M.D.; Effie Singas, M.D.; Bashar Zleik, M.D.; Harly Greenberg, M.D., F.A.A.S.M.

Division of Pulmonary, Critical Care and Sleep Medicine, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY

Obstructive sleep apnea (OSA) in patients with myasthenia
gravis (MG) may be caused by reduced pharyngeal dilator
muscle activity. We report a patient with anti-muscle kinase
receptor MG with severe OSA and hypoventilation that resolved
upon successful treatment of MG despite a 60-lb weight gain.
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M

yasthenia gravis (MG) may contribute to development of
obstructive sleep apnea (OSA) by inducing pharyngeal
dilator muscle weakness, although not all studies have demonstrated this association.1-3 MG is often caused by acetylcholine
receptor antibodies (AchR-Abs) blocking neuromuscular transmission. However, approximately 40% of MG patients who do
not have AchR-Abs have anti-muscle kinase receptor antibodies
(anti-MuSKR-Ab). This likely alters clustering of acetylcholine receptors during neuromuscular junction formation.4 MG
has a variable clinical course that may be exacerbated by stress
including infection, exertion or various drugs that may lead to
“myasthenic crisis” with respiratory compromise.

with average volume adjusted pressure support (AVAPS) to
treat OSA and hypoventilation with a targeted tidal volume of
400 mL, EPAP 8 cm H2O, IPAPmax 25, IPAPmin 12 cm H2O.
Although hypercapnia improved (ABG: pH 7.38 / PCO2
47 mm Hg / PO2 77 / HCO3- 27 mm Hg), fatigue, dyspnea,
and weakness persisted. Subsequent serology revealed antiMuSKR-Abs prompting treatment with plasma exchange,
maintenance mycophenolate mofetil and prednisone, which
normalized her neurological exam and muscle weakness. After
3 months, despite a 60-lb weight increase (BMI 35 kg/m2),
repeat diagnostic PSG showed resolution of OSA and nocturnal
hypoventilation (AHI = 1/h; T90% = 0) with normal serum
HCO3- (25 mmol/L).

REPORT OF CASE

DISCUSSION

A 45-year-old female with 6 months of headaches, weakness, dysarthria, dysphagia, and 60-pound weight loss (BMI 26
kg/m2) was admitted for hypercapnic respiratory failure (ABGsupplemental O2: pH 7.27 / PCO2 60 mm Hg / PO2 99 mm
Hg / HCO3- 28 mmol/L). Neurological evaluation showed fatigable diplopia, ptosis, and bi-facial and genioglossus weakness.
Neck flexor and extensor and proximal extremity muscles were
spared. Formal swallowing evaluation conﬁrmed dysphagia.
However, AchR-Abs were negative. Electromyography, nerve
conduction studies and repetitive nerve stimulation (no decremental response) were not consistent with MG. No deﬁnitive
neurological diagnosis was made. The patient was discharged
on nocturnal bilevel positive airway pressure for treatment of
persistent hypercapnia (ABG after 2 weeks: pH 7.34 / PCO2
62 mm Hg / PO2 84 mm Hg / HCO3- 35 mmol/L). Pulmonary
function assessment revealed a moderate restrictive ventilatory
defect (FEV1 61%, FVC 63% predicted, FEV1/FVC% = 79%),
reduced maximum inspiratory and expiratory pressures (-52,
+36 cm H2O). Split-night polysomnography (PSG) showed
OSA with an apnea-hypopnea index (AHI) of 31/h, with
T90% = 31%. Nocturnal noninvasive ventilation was optimized

Both insufﬁcient neural drive to upper airway dilator muscles
and anatomic factors that compromise the upper airway
contribute to the pathophysiology of OSA. In MG, muscular
strength varies based on muscle exertion, fluctuating levels of
autoantibodies that affect neuromuscular junction transmission,
and other factors. The impact of MG may not be uniformly
distributed, as greater effects are often manifested in speciﬁc
muscle groups.4 In our patient, the exacerbation and improvement of MG, manifested by development and resolution of
fatigable diplopia, ptosis, bi-facial and genioglossus weakness, dysarthria, and dysphagia paralleled the course of OSA
and hypercapnic respiratory failure. Despite gaining 60 pounds
after successful MG treatment, OSA and hypercapnia resolved.
Only one study reported improvement of OSA after treatment
of MG, but with thymectomy.1 Our patient represents the ﬁrst
report of OSA resolution after treatment of anti-MuSKR-Abpositive MG.
Several studies have shown an increased prevalence of OSA
in MG with AchR-Abs.3 In one study of 100 AchR-Ab-positive
MG patients, 36% had an AHI > 5.2 In contrast, a study of 17
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AchR-Ab-positive MG patients found no correlation between
MG and OSA.3 However, these studies did not report antiMuSKR-Ab-positive MG.
Anti-MuSKR-Ab occurs in approximately 4% of patients
with MG, compared with 90% of patients with AchR-Abs.
Disease onset can be at any age, with female predominance.
Weakness can be more severe than in AchR-Ab-positive MG.
The diagnosis can be challenging since nerve conduction
studies and electromyography are often normal. Further, antiMuSKR-Ab MG is associated with distinct patterns of weakness compared to AchR-Ab-positive MG. One type presents
with faciopharyngeal weakness. The other is associated with
neck extensor, respiratory, and proximal muscle weakness.4
Acetylcholinesterase inhibitors are less effective in this form of
MG. Therapeutic response is better with plasma exchange and
immunosuppressive therapy.
Patients with MG who present with sleep related complaints
should be evaluated for OSA and nocturnal hypoventilation.
Neurologists and sleep medicine professionals should be aware
of the association between MG, OSA, and hypoventilation and
consider testing for Anti-MuSKR-Ab if AchR-Abs are negative. Variations in disease state and antibody types of MG may
influence the severity of sleep disordered breathing. Likewise,
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treatment of MG may result in improvement of MG, OSA, and
hypoventilation.
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